Basal Cell Nevus Syndrome Clinical Trial
Official title:
Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
The investigators will be testing whether aminolevulinate-based (Levulan™) Photodynamic Therapy (PDT) shows effectiveness in the treatment and prevention of cutaneous basal cell carcinoma (BCC) in Basal Cell Nevus Syndrome (BCNS) patients. Levulan™ PDT is an FDA-approved method widely used currently for squamous precancers of the skin. The investigators hypothesize that PDT will provide exceptional benefit in the BCNS population because PDT is nonmutagenic, nonscarring, and can be safely repeated many times. Additionally, the study will investigate whether there are any differences in tumor clearance between the Blu-U® (blue lamp) and Aktilite™(red lamp) therapies.
This is a pilot intra-patient comparative study to evaluate the ability of cyclic
Photodynamic Therapy (PDT) using Red (635 nm) or Blue (400 nm) light with 5-Aminolevulinic
acid, to eliminate BCC skin cancers that occur in patients with Basal Cell Nevus Syndrome
(Gorlin-Goltz Syndrome).
Patients will receive 3 cycles of Red light and Blue light PDT treatments, for a total of 6
treatments, over a 4 month period. Cycles will be spaced 2 months apart. Each cycle consists
of a double course of PDT treatment with treatments spaced one week apart. Every subject will
be treated with two light sources, blue and red, according to randomized assignments made to
left side or right side of the body. There will be a final assessment visit at month 6.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02550678 -
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00555633 -
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
|
N/A | |
| Recruiting |
NCT03483441 -
Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS
|
Phase 1 | |
| Active, not recruiting |
NCT03467789 -
Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
| Completed |
NCT02762084 -
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
|
Phase 2 | |
| Terminated |
NCT04308395 -
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
|
Phase 3 | |
| Withdrawn |
NCT03767439 -
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
|
Phase 2 | |
| Completed |
NCT04416516 -
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
|
Phase 2 | |
| Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
| Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
| Terminated |
NCT02303041 -
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02100371 -
Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome
|
N/A | |
| Completed |
NCT03703310 -
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
|
Phase 3 | |
| Completed |
NCT00957229 -
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
|
Phase 2 | |
| Completed |
NCT01556009 -
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
|
Phase 2 |